Search - tctmd.com

Displaying 481 - 500 of 892

Sort: Relevancy | Date

New Cardiogenic Shock Definitions Create Common Lexicon for Healthcare Teams

News Conference News SCAI 2019

New Cardiogenic Shock Definitions Create Common Lexicon for Healthcare Teams

Yael L. Maxwell

May 22, 2019

Taking Ticagrelor? Frank, Proactive Patient Conversations are Needed to Help With Adherence

News Daily News

Taking Ticagrelor? Frank, Proactive Conversations are Needed to Help With Adherence

Yael L. Maxwell

May 17, 2019

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

News Daily News

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Michael O'Riordan

May 06, 2019

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

News Daily News

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

Yael L. Maxwell

April 24, 2019

No Need for Niacin? Meta-analysis Argues the End Is Nigh

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

Initiative Helps Low-Resource Chinese Hospitals Provide Better ACS Care

News Daily News

Initiative Helps Low-Resource Chinese Hospitals Provide Better ACS Care

April 17, 2019

Less Not Always More When Medicating Frail, Elderly Acute MI Patients

News Daily News

Less Not Always More When Medicating Frail, Elderly Acute MI Patients

April 16, 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

March 26, 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

News Daily News

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Michael O'Riordan

March 08, 2019

Under 40, or 10 Years Older: MI Survivors Face Similar Long-term Mortality Risks

News Conference News ACC 2019

Under 40, or 10 Years Older: MI Survivors Face Similar Long-term Mortality Risks

March 07, 2019

Quality of CAD Care Varies by Type of Medicare Coverage

News Daily News

Quality of CAD Care Varies by Type of Medicare Coverage

February 20, 2019

Lower Statin Adherence Linked to Higher Mortality Risk, Even Among Patients With Established ASCVD

News Daily News

Lower Statin Adherence Linked to Higher Mortality Risk, Even Among Patients With Established ASCVD

February 15, 2019

Should Pioglitazone Be Used More for Secondary Stroke Prevention in Prediabetes?

News Conference News ISC 2019

Should Pioglitazone Be Used More for Secondary Stroke Prevention in Prediabetes?

February 14, 2019

Cilostazol-Based DAPT Safe, Effective in Patients at High Risk for Recurrent Stroke

News Conference News ISC 2019

Cilostazol-Based DAPT Safe, Effective in Patients at High Risk for Recurrent Stroke

February 12, 2019

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

News Daily News

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Michael O'Riordan

February 08, 2019

Intensive BP Lowering May Have Cognitive Benefits: SPRINT MIND

News Daily News

Intensive BP Lowering May Have Cognitive Benefits: SPRINT MIND

February 04, 2019

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.